Zybrivo (sintilimab), developed by Innovent Biologics, has won a positive opinion from the CHMP, the human medicines committee of the European Medicines Agency, as a treatment for adults with non-squamous non-small cell lung cancer. The EMA listed it among seven new medicines the committee recommended at its November 2026 meeting. In a Nov. 15, 2026 announcement, Innovent described this as the first positive CHMP opinion the company has obtained.
What was recommended
According to Innovent, the committee supports granting marketing authorization for Zybrivo in combination with chemotherapy for adults whose non-squamous NSCLC is advanced. Under the proposed indication, Zybrivo would be used with pemetrexed and platinum-based chemotherapy as a first-line option for patients without EGFR or ALK genomic tumor aberrations.
The final say rests with the European Commission, which Innovent expects to rule in the coming months. An approval would apply across all 27 EU member states, along with Iceland, Norway and Liechtenstein, the company said.
The trial behind the opinion
Innovent said the recommendation draws on ORIENT-11 (NCT03607539), a Phase 3 study conducted at multiple centers in which neither patients nor investigators knew who received the drug and who received placebo. It included 397 adults with locally advanced, metastatic or recurrent non-squamous NSCLC whose tumors carried no EGFR or ALK genomic aberrations; PD-L1 expression was not an entry criterion. Two participants received sintilimab for every one given placebo, with both groups also receiving chemotherapy. Progression-free survival served as the primary endpoint, judged by an independent radiological panel that was blinded to treatment.
Innovent reported that adding sintilimab to chemotherapy cut the hazard of progression or death by 52%, with median progression-free survival of 8.9 months versus 5.0 months for the placebo group. The company said the combination also lowered the hazard of death by 35%, with median overall survival reaching 24.2 months compared with 16.8 months. Side effects matched the established profiles of PD-1 inhibitors and the chemotherapy drugs used, and no new safety signals emerged, according to Innovent.
Background on the drug and the disease
Sintilimab is a fully human IgG4 monoclonal antibody that targets PD-1. Innovent says China has approved it for ten indications and that roughly 3 million patients there have been treated with it.
European figures cited by Innovent show lung cancer is the deadliest cancer in the EU, causing about one in five of the bloc's cancer deaths. An estimated 319,000 people there received a lung cancer diagnosis in 2022, and non-small cell lung cancer is the most frequent type, making up 85–90% of cases.
At the same November meeting, the CHMP also recommended Aumseqa (aumolertinib) for non-small cell lung cancer, the EMA said.



